Viel Erika, Curtit Elsa, Mansi Laura, Vignot Stéphane
CHU J.-Minjoz, service d'oncologie médicale, boulevard Fleming, 25030 Besançon, France.
Bull Cancer. 2012 Feb 1;99(2):181-9. doi: 10.1684/bdc.2011.1385.
EGFR may be considered as an old target, which can be inhibited both by monoclonal antibodies and tyrosine kinase inhibitors. Those molecular targeted strategies are now approved in a wild range of tumors: colorectal cancer, lung cancer, pancreatic cancer and head and neck cancer. This paper proposes to describe the development of anti-EGFR drugs, highlighting several strategies points. Predicting biomarkers have been extensively studied for these agents, sustaining the hallmarks of the development of molecular targeting drugs.
表皮生长因子受体（EGFR）可被视为一个古老的靶点，单克隆抗体和酪氨酸激酶抑制剂均可对其产生抑制作用。目前，这些分子靶向策略已在多种肿瘤中获批应用，包括结直肠癌、肺癌、胰腺癌和头颈癌。本文旨在描述抗EGFR药物的发展历程，并重点阐述几个策略要点。针对这些药物，预测性生物标志物已得到广泛研究，这也支撑了分子靶向药物发展的特点。
